{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.6.3', 'Primary and Secondary Endpoint Analysis', 'Study endpoints will be evaluated for all subjects from Baseline to Week 24 the EOT Visit.', '9.6.3.2.1 Stratification of Proptosis and CAS Response into Four Responses Categories', 'To further explore the response based on both proptosis and CAS reduction, each subject will be', 'classified into one of 4 response categories at Week 24 EOT:', 'High responders: Subjects who had a reduction in both proptosis and CAS of 3 or more', '(3) from Baseline in the study eye, and no deterioration in the fellow eye (i.e., increase', 'in CAS > 2 points or increase in proptosis > 2 mm).', 'Responders: Subjects who had a reduction in both CAS and proptosis of 2 or more (but', 'less than 3) from Baseline in the study eye, and no deterioration in the fellow eye.', 'Low Responders: Subjects who had a reduction in both CAS and proptosis of 1 or more', '(but less than 2) from Baseline in the study eye, and no deterioration in the fellow eye.', 'Non-Responders: Subjects who did not fit into any of the above categories, or were not', 'present for the Week 24 EOT evaluation', '17.1', 'Administrative Appendix', 'Sponsor', 'Representative', 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Mobile telephone number:', 'Fax number:', 'Email:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 29 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '2', 'SYNOPSIS', 'Protocol Title: Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab', '(HZN-001) Treatment in Subjects with Thyroid Eye Disease (OPTIC-X)', 'Protocol Number: HZNP-TEP-302', 'Phase: 3', 'Protocol Version: 3.0', 'Test Drug: Teprotumumab (HZN-001)', 'Indication: Thyroid Eye Disease (TED)', 'Number and Country of Study Sites: Up to 16 study centers in the United States and Europe.', 'Objectives:', 'The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of TED in subjects', 'who participated in the lead-in study (HZNP-TEP-301) and who were either proptosis non-responders at', 'Week 24 of HZNP-TEP-301 or were proptosis responders at Week 24 but meet the criteria for re-treatment due', 'to relapse (see Section 9.3.4) during the Follow-Up Period of HZNP-TEP-301.', 'Primary Objective', 'The primary objective is to evaluate the effect of teprotumumab on the proptosis responder rate (i.e., the', 'percentage of subjects with a > 2 mm reduction from Baseline in the study eye without deterioration [> 2 mm', 'increase] of proptosis in the fellow eye) at Week 24.', 'Secondary Objectives', 'Secondary objectives will evaluate the effect of teprotumumab on the following:', '1. Percentage of subjects with a Clinical Activity Score (CAS) value of 0 or 1 at Week 24 in the study eye.', '2. Mean change from Baseline to Week 24 in proptosis measurement in the study eye.', '3. Diplopia responder rate (i.e., the percentage of subjects with baseline diplopia > 0 in study eye who have', 'a', 'reduction of > 1 grade with no corresponding deterioration 1> 1 grade worsening] in the fellow eye) at', 'Week 24.', \"4. Mean change from Baseline to Week 24 in the Graves' Ophthalmopathy Quality of Life (GO-QoL)\", 'questionnaire overall score.', 'Exploratory Objectives', 'Exploratory objectives will evaluate the effect of teprotumumab on the following:', '1.', 'The overall responder rate (percentage of subjects with > 2-point reduction in CAS AND > 2 mm', 'reduction in proptosis from Baseline, provided there is no corresponding deterioration [> 2-point/mm', 'increase] in CAS or proptosis in the fellow eye) at Week 24.', '2. Clinical Measures of Severity individual response status frequencies and percentage of responders for each', 'component of clinical severity at Week 24.', '3. Mean change from Baseline to Week 24 in the CAS.', '4. Overall responder rate at Week 24 stratified by the level of response (high responders, responders, low', 'responders, and non-responders; see Section 9.6.3.2.1 for definitions).', '5. Mean change from Baseline to Week 24 in the GO-QoL questionnaire visual functioning (VF) and', 'appearance (A) subscale scores.', '6. Mean change from Baseline to Week 24 on the motility component of the Clinical Measures of Severity.', '7.', 'Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure and understand PK-PD', 'relationships.', 'Study Design:', 'This is a multi-center, open-label extension study of HZNP-TEP-301 examining the safety and efficacy of', 'teprotumumab in the treatment of TED in adult subjects. Subjects who complete the 24-week double-masked', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 30 of 118']\n\n###\n\n", "completion": "END"}